KR20240008356A - 헤모글로빈 조정제의 고체 형태 - Google Patents

헤모글로빈 조정제의 고체 형태 Download PDF

Info

Publication number
KR20240008356A
KR20240008356A KR1020237043235A KR20237043235A KR20240008356A KR 20240008356 A KR20240008356 A KR 20240008356A KR 1020237043235 A KR1020237043235 A KR 1020237043235A KR 20237043235 A KR20237043235 A KR 20237043235A KR 20240008356 A KR20240008356 A KR 20240008356A
Authority
KR
South Korea
Prior art keywords
compound
crystalline
dsc
hemoglobin
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237043235A
Other languages
English (en)
Korean (ko)
Inventor
스테판 디. 페어런트
트래비스 리 휴스턴
코트니 에스. 존슨
팡 왕
Original Assignee
글로벌 블러드 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글로벌 블러드 테라퓨틱스, 인크. filed Critical 글로벌 블러드 테라퓨틱스, 인크.
Publication of KR20240008356A publication Critical patent/KR20240008356A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
KR1020237043235A 2021-05-14 2022-05-13 헤모글로빈 조정제의 고체 형태 Pending KR20240008356A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188833P 2021-05-14 2021-05-14
US63/188,833 2021-05-14
PCT/US2022/029289 WO2022241278A1 (en) 2021-05-14 2022-05-13 Solid forms of a modulator of hemoglobin

Publications (1)

Publication Number Publication Date
KR20240008356A true KR20240008356A (ko) 2024-01-18

Family

ID=82020064

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043235A Pending KR20240008356A (ko) 2021-05-14 2022-05-13 헤모글로빈 조정제의 고체 형태

Country Status (13)

Country Link
US (2) US11851424B2 (https=)
EP (1) EP4337659A1 (https=)
JP (1) JP2024520897A (https=)
KR (1) KR20240008356A (https=)
CN (1) CN117337285A (https=)
AR (1) AR126649A1 (https=)
AU (1) AU2022273787B2 (https=)
BR (1) BR112023021606A2 (https=)
CA (1) CA3219786A1 (https=)
MX (1) MX2023012156A (https=)
TW (1) TW202311254A (https=)
WO (1) WO2022241278A1 (https=)
ZA (1) ZA202309517B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250041312A1 (en) * 2021-12-10 2025-02-06 Global Blood Therapeutics, Inc. Methods of administering a modulator of hemoglobin
TW202515579A (zh) * 2023-06-13 2025-04-16 美商全球血液治療公司 投予血紅素的調節劑之方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
SG10201802911RA (en) * 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
HRP20220295T1 (hr) 2018-11-19 2022-05-13 Global Blood Therapeutics, Inc. Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin
WO2022241286A1 (en) * 2021-05-14 2022-11-17 Global Blood Therapeutics, Inc. Methods of making a modulator of hemoglobin

Also Published As

Publication number Publication date
MX2023012156A (es) 2023-10-26
BR112023021606A2 (pt) 2023-12-19
CN117337285A (zh) 2024-01-02
ZA202309517B (en) 2024-06-26
EP4337659A1 (en) 2024-03-20
US20220363674A1 (en) 2022-11-17
US11851424B2 (en) 2023-12-26
AR126649A1 (es) 2023-11-01
US12473277B2 (en) 2025-11-18
AU2022273787B2 (en) 2025-04-03
JP2024520897A (ja) 2024-05-27
AU2022273787A1 (en) 2023-10-26
TW202311254A (zh) 2023-03-16
US20240076290A1 (en) 2024-03-07
CA3219786A1 (en) 2022-11-17
WO2022241278A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
ES2750676T5 (en) Crystalline dihydrochloride hydrate salt of omecamtiv mecarbil and process for its preparation
KR20160118204A (ko) 2-하이드록시-6-((2-(1-이소프로필-1h-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체
US12473277B2 (en) Solid forms of a modulator of hemoglobin
US20080200474A1 (en) Novel flunarizine salt forms and methods of making and using the same
EP3752500A1 (en) Solid-state forms of abemaciclib, their use and preparation
EP3853200B1 (en) Erbumine salt of treprostinil
HK40101540A (zh) 血红蛋白之调节剂的固体形式
US20250304635A1 (en) Birinapant polymorph h
AU2015392050B2 (en) Fumarate of pyridylamine compound and crystals thereof
HK40119275A (zh) 新生霉素类似物与脯氨酸的共晶体形式
KR20250107260A (ko) 2-(4-(2-(7,8-디메틸-[1,2,4]트리아졸로[1,5-a] 피리딘-6-일)-3-이소프로필-1H-인돌-5-일)피페리딘-1-일)아세트아미드 염 및 그의 결정질 형태
WO2024023796A1 (en) Polymorphs, co-crystals and solvates of fruquintinib, processes for the preparation and use thereof
EA043230B1 (ru) Эрбуминовая соль трепростинила
HK1218544B (en) Salt of omecamtiv mecarbil and process for preparing salt

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701